P

Precision AQ

Data-driven drug access and launches

Regulatory Manager

Full-TimeUpdated on 10/23/2026
$106k - $151k+ Discretionary annual bonus
Senior
Bachelor's
Remote in USA
RemoteRemote role; domestic and international travel, including overnight stays, is required.
Biology & BiotechRegulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree or equivalent experience, ideally in a scientific or healthcare discipline.
  • Computer literacy, including Microsoft Office and Office 365.
  • Fluency in English.
  • At least five years of relevant regulatory affairs experience.
  • Informed knowledge of all aspects of the drug development process, including regulatory milestones.
  • Specialized knowledge of regulatory activities for at least one major region, including the European Union or United States, and submissions such as INDs/CTAs, amendments, Scientific Advice Procedures, and post-approval submissions.
  • Ability to understand clinical and pre-clinical study results and help interpret them for regulatory positions and strategy.
  • Knowledge of clinical trial methodology, including working knowledge of protocols and indications being studied.
  • Knowledge and expertise in regulations and guidance supporting pharmaceutical development.
  • Availability for domestic and international travel, including overnight stays.
  • Ability to manage multiple varied tasks in a fast-moving environment and maintain good records.
  • Ability to work and plan independently as well as in a team environment.
  • Ability to motivate project team members to meet timelines and project goals.
  • Ability to resolve project-related problems and prioritize workload to meet deadlines with little support from management.
  • Ability to assess proactively how to improve processes and people effectiveness.
  • Ability to collect data to a consistently high standard.
  • Ability to communicate verbally and in writing and conduct formal presentations to audiences including colleagues, investigative staff, and clients.
  • Ability to understand financial management at a basic level is preferred.
  • Graduate or postgraduate education is preferred.
Responsibilities
  • Provide regulatory guidance throughout the clinical development life cycle.
  • Compile, coordinate, and review applications to Regulatory Authorities, including CTA/IND submissions, annual reports, routine amendments, scientific advice and regulatory authority meetings, orphan designations, pediatric planning, and marketing applications; provide strategic regulatory input as required.
  • Develop and/or review documents for submission to Regulatory Authorities and/or Ethics Committees to ensure compliance with regulatory standards.
  • Represent Global Regulatory Affairs at project team meetings with external and internal customers.
  • Work within project teams and, where necessary, lead projects for a region or globally.
  • Oversee and coordinate Regulatory Affairs Specialists to achieve submission targets for contracted programs.
  • Maintain project plans, project trackers, and regulatory intelligence tools within assigned responsibilities, and keep Regulatory Leadership updated.
  • Assist in developing Regulatory Affairs Specialists and other operational-area staff as required.
  • Provide input into regulatory strategy and timeline development for new study opportunities, as required.
  • Assist in establishing company standards to ensure the quality of submitted information.
  • Participate in maintaining and executing corporate quality initiatives across business units within clinical solutions.
  • Keep current and continually expand knowledge of laws, regulations, and guidelines governing drug development and approval.
  • Provide ICH GCP guidance, advice, and training to internal and external clients.
  • Represent Global Regulatory Affairs at business development meetings.
Desired Qualifications
  • Graduate or postgraduate education.
  • Basic understanding of financial management.

About the company

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 17, 2026 hires Yahya Anvar and Emma Hawe deepen AI and HTA capabilities.
  • August 12, 2026 Candice Subero hire boosts marketing-led customer engagement and commercial growth.
  • Precision AQ’s 2025 Phluence investment advances agentic patient solutions, reducing post-Rx service costs.

What critics are saying

  • Precision AQ reported $314.5 million revenue in 2024, down 7%, signaling slower growth.
  • Phluence integration in November 2025 risks distracting teams while AI patient-service economics remain unproven.
  • If pharma shifts to in-house AI access tools, Precision AQ’s HUB model weakens.

What makes Precision AQ unique

  • Precision AQ works with all top 30 pharma companies and 350+ active engagements in 2026.
  • Its 2024 rebrand unified pricing, HEOR, medical affairs, and omnichannel capabilities under one platform.
  • Precision AQ has launched over 450 drugs, creating embedded launch expertise across therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Parental Leave
  • Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...